POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.

David K. Lau,David Cunningham,Angela Gillbanks,Richard Crux,Rachel Powell,Eleftheria Kalaitzaki,Nicola E. Annels,Francesco Sclafani,Marco Gerlinger,Ian Chau,Ian Tomlinson,Naureen Starling,Hardev Pandha,David N. Church,Tony Dhillon

POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.

2019

David K. Lau
David Cunningham
Angela Gillbanks
Richard Crux
Rachel Powell
Eleftheria Kalaitzaki
Nicola E. Annels
Francesco Sclafani
Marco Gerlinger
Ian Chau
Ian Tomlinson
Naureen Starling
Hardev Pandha
David N. Church
Tony Dhillon

TPS3615Background: Colon cancer with deficient mismatch repair (dMMR) and POLE mutations are characterised by a high tumor mutational burden (TMB) and an immunogenic lymphocyte infiltrate. Approxim...

Keywords:

Exonuclease
Avelumab
Colorectal cancer
Adjuvant
Randomized controlled trial
Cancer research
Mutant
Pathology
Chemotherapy
Medicine
DNA mismatch repair
Lymphocyte

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations